Instruction for use: Grippferon

Dosage form: Nasal drops; Nasal dosing spray

Active substance: Interferonum alpha-2b

ATX

L03AB05 Interferon alfa-2b

Pharmacological group:

Cytokine [Interferons]

The nosological classification (ICD-10)

J06 Acute upper respiratory tract infections of multiple and unspecified locations: Frequent colds of viral diseases; Infections of ENT organs; Acute respiratory illness of influenza nature; Pain for colds; Acute catarrhal disease; Cold; Colds; Colds; Respiratory infection; Seasonal catarrhal disease; Seasonal colds; Pain in infectious and inflammatory diseases of the upper respiratory tract; Bacterial infections of the upper respiratory tract; Bacterial infections of the respiratory system; Viral respiratory disease; Viral respiratory tract infections; Inflammatory disease of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract with difficult to separate sputum; Inflammatory respiratory disease; Secondary infections for colds; Difficult sputum separation in acute and chronic respiratory diseases; Upper respiratory tract infections; Infections of the upper respiratory tract; Respiratory tract infections; Respiratory and lung infections; Infectious-inflammatory diseases of the upper respiratory tract; Infectious-inflammatory diseases of the upper respiratory tract and ENT organs; Infectious-inflammatory diseases of the upper respiratory tract in adults and children; Infectious-inflammatory diseases of the upper respiratory tract; Infectious inflammation of the respiratory tract; Respiratory tract infection; Qatar upper respiratory tract; Catarrh of the upper respiratory tract; Catarrh of the upper respiratory tract; Catarrhal phenomena from the upper respiratory tract; Cough in diseases of the upper respiratory tract; Cough for colds; ARVI; ARI; ARI with phenomena of rhinitis; Acute respiratory infection; Acute infectious-inflammatory disease of the upper respiratory tract; Acute respiratory disease; Persecution in the throat or nose; Respiratory and viral infections; Respiratory diseases; Respiratory infections; Recurrent respiratory tract infections; Secondary infections with influenza; Influenza states; Feverish conditions for influenza

J11 Influenza, virus not identified: Influenza; Influenza in the early stages of the disease; Influenza in children; cold in the chest; Begins flu-like condition; Acute disease parainfluenza; parainfluenza; parainfluenza state; influenza epidemics; The pains of the influenza

Z29.1 Prophylactic immunotherapy: Vaccination against viral infections; donor Vaccination; Vaccination and revaccination; Vaccination of newborns; Vaccination against hepatitis B; Immunization; Correction of the immune status; Therapeutic and prophylactic immunization; Preventive immunization; Specific immunoprophylaxis; Stimulation of the processes of nonspecific immunit

Composition

Nasal drops 1 ml

active substance: Interferon alpha-2b human recombinant at least 10,000 IU / mL

Auxiliary substances: disodium edetate dihydrate - 0.5 mg; Sodium chloride - 4.1 mg; Sodium hydrogen phosphate dodecahydrate - 11.94 mg; Potassium dihydrogen phosphate - 4.54 mg; Povidone 8000 - 10 mg; Macrogol 4000 - 100 mg; Purified water - up to 1 ml

Spray nasal dosed 1 ml / 1 dose

active substance: Interferon alpha-2b human recombinant not less than 10000/500 IU

Auxiliary substances: disodium edetate dihydrate - 0.5 mg; Sodium chloride - 4.1 mg; Sodium hydrogen phosphate dodecahydrate - 11.94 mg; Potassium dihydrogen phosphate - 4.54 mg; Povidone 8000 - 10 mg; Macrogol 4000 - 100 mg; Purified water - up to 1 ml

Description of dosage form

Drops, spray: the solution is clear, colorless or light yellow in color.

Pharmachologic effect

Mode of action - antiviral, anti-inflammatory, immunomodulating.

Pharmacodynamics

The drug has an immunomodulatory, anti-inflammatory and antiviral effect.

Pharmacokinetics

In case of intranasal application, the concentration of the active substance reached in the blood is significantly lower than the detection limit (the limit of determination of interferon alpha-2b is 1-2 IU / ml) and has no clinical significance.

Indication of the Grippferon

Prevention and treatment of influenza and ARVI in children and adults.

Contraindications

Individual intolerance to interferon preparations and components that make up the drug;

Severe forms of allergic diseases.

Application in pregnancy and breastfeeding

Grippferon® is approved for use throughout the gestation period. Has no limitations to use during lactation.

Side effects

Allergic reactions.

Interaction

The use of intranasal vasoconstrictive drugs in conjunction with the preparation Grippferon® is not recommended; This contributes to the additional drying of the nasal mucosa.

Dosing and Administration

Intranasally.

At the first sign of the disease, Grippferon® should be applied within 5 days:

- at the age of 1 year - 1 drop / dose (500 ME) in each nasal passage 5 times a day (single dose - 1000 ME, daily dose - 5000 ME);

- at the age of 1 to 3 years - 2 drops / dose in each nasal passage 3-4 times a day (single dose - 2000 ME, daily dose - 6000-8000 ME);

- at the age of 3 to 14 years - 2 drops / dose in each nasal passage 4-5 times a day (single dose - 2000 ME, daily dose - 8000-10000 ME);

- with 15 years and adults - 3 drops / dose in each nasal passage 5-6 times a day (single dose - 3000 ME, daily dose - 15000-18000 ME).

With a view to preventing ARVI and influenza:

- in case of contact with the patient and / or during supercooling, the drug is instilled / injected in a single age-related dosage 2 times a day;

- with a seasonal increase in the incidence of the drug, the drug is injected / injected into the dosed dosage once in the morning with a temporary 24-48 h;

- if necessary, preventive courses are repeated.

Drops. After each instillation, it is recommended to massage the wings of the nose with your fingers for several minutes to distribute the drug evenly in the nasal cavity.

Spray. In order to get rid of the protective cap, apply it to the spraying mechanism (1 dose - 1 push). Before the first tap, press the sprayer several times to deliver the spray clouds.

Overdose

Data on drug overdose are absent.

Special instructions

Influence on the ability to drive vehicles or perform work that requires an increased speed of physical and mental reactions. The drug does not affect the ability to drive vehicles and mechanisms.

Release Form

Nasal drops, 10000 IU / ml. In plastic bottles with dispensers-droppers for 5 or 10 ml. In a pack of cardboard 1 fl.

Spray nasal dosed, 500 IU / dose. In plastic bottles with dispensers of 10 ml (200 doses). In a pack of cardboard 1 fl.

Manufacturer

ZAO "Firn M". 143390, Moscow, etc. Kokoshkino Str. Dzerzhinsky, 4.

Claims of consumers should be sent to the address of CJSC "Firn M".

Tel: (495) 956-15-43.

Conditions of supply of pharmacies

Without recipe.

Storage conditions of the drug Grippferon

At a temperature of 2-8 ° C.

Keep out of the reach of children.

Shelf life of the drug Grippferon

2 years. The opened vial should not be stored for more than 30 days.

Do not use after the expiry date printed on the package.